Poster: CML-231 Long-Term Results of Tyrosine Kinase Inhibitors Discontinuation in Patients With Chronic Myeloid Leukemia

Clinical Lymphoma Myeloma and Leukemia(2022)

Cited 0|Views14
No score
Abstract
The probability of MMR loss after 5 years of follow-up was 53%. Molecular relapses were rare after 2 years without TKI therapy. However, molecular monitoring with a frequency of 2-3 times a year during long-term observation in TFR is mandatory for patients' safety, especially in those with detectable MRD.
More
Translated text
Key words
CML,chronic myeloid leukemia,treatment-free remission,long-term follow-up
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined